DelveInsight’s “Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Social Anxiety Disorder market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Social Anxiety Disorder market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Social Anxiety Disorder: An Overview
Social Anxiety disorder (SAD), also called Social Phobia, is the most common mental health condition which causes extreme fear in social settings and an intense, persistent fear of being watched and judged by others. People with social anxiety disorder have trouble talking to people, meeting new people, attend social gatherings, which can also affect day-to-day activities.
Social anxiety disorder can make a person fear being judged or scrutinized by others. Patients may understand their fears are irrational or unreasonable but feel powerless to overcome them. Social anxiety differs from shyness, which is usually short-term and doesn’t disrupt one’s life. Social anxiety is persistent and debilitating. It can affect one’s ability to work, attend school, and develop close relationships with people outside their family.
Symptoms of Social Anxiety disorder may include physical symptoms, which can be blushing, nausea, excessive sweating, trembling or shaking, difficulty in speaking, dizziness or lightheadedness, and rapid heart rate.
Social Anxiety Disorder Market Key Facts
According to the National Institute of Mental Health (NIMH), approximately 7.1% of US adults had a social anxiety disorder in the past year. Out of the adults with social anxiety disorder in the past year, an estimated 29.9% had serious impairment. Also, data from the National Comorbidity Survey reveals that social anxiety disorder is the third most common psychiatric condition after major depression and alcohol dependence.
As per the Anxiety and Depression Association of America (ADAA) 2021, social anxiety disorder affects around 15 million adults or 6.8% of US population. Many people are frequently misdiagnosed as a result of the disease. Thirty-six people with social anxiety disorder experience symptoms for 10 years or more before seeking care, according to a 2007 ADAA survey.
According to Cambridge University (2020), epidemiologic surveys conducted across Europe indicated that the lifetime prevalence of Social anxiety disorder in the general population is close to 7%.
According to the National Institute of Health and Care Excellence (NICE), the lifetime prevalence of Social Anxiety disorder is 12% in the UK population.
As per Judith et. Al. (2017), the lifetime prevalence of Social Anxiety Disorder in Germany is found to be around 12%.
in US adults was observed in the age groups 18-29, 30-44, 45-59, and 60+ years was 9.1%, 8.7%, 6.8%, and 3.1%.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Social Anxiety Disorder market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Social Anxiety Disorder market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Social Anxiety Disorder Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Social Anxiety Disorder Epidemiology, Segmented as –
Total treated cases of Social Anxiety disorder in the 7MM [2019-2032]
Total Prevalent Cases of Social Anxiety Disorder in the 7MM (2019–2032)
Age-specific Prevalence of Social Anxiety Disorder in the 7MM (2019–2032)
Severity-specific cases of Social Anxiety Disorder in the 7MM (2019–2032)
Gender-specific Prevalence of Social Anxiety Disorder in the 7MM (2019–2032)
Total diagnosed cases of Social Anxiety Disorder in the 7MM (2019-2032)
Social Anxiety Disorder Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Social Anxiety Disorder market or expected to be launched during the study period. The analysis covers the Social Anxiety Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Social Anxiety Disorder pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Social Anxiety Disorder Market Will Evolve and Grow by 2032 @
Social Anxiety Disorder Therapeutics Analysis
The dynamics of the SAD therapeutic market are anticipated to change in the coming years owing to the improvement in the research and development undertaking. Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with SAD
The Leading Companies in the Social Anxiety Disorder Therapeutics Market Include:
And Many Others
Social Anxiety Disorder Emerging Products Covered in the Report Include:
PH94B: Vistagen Therapeutics
VQW-765: Vanda Pharmaceuticals
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Social Anxiety Disorder Competitive Intelligence Analysis
4. Social Anxiety Disorder Market Overview at a Glance
5. Social Anxiety Disorder Disease Background and Overview
6. Social Anxiety Disorder Patient Journey
7. Social Anxiety Disorder Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Social Anxiety Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Social Anxiety Disorder Unmet Needs
10. Key Endpoints of Social Anxiety Disorder Treatment
11. Social Anxiety Disorder Marketed Products
12. Social Anxiety Disorder Emerging Drugs and Latest Therapeutic Advances
13. Social Anxiety Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Social Anxiety Disorder Market Outlook (In US, EU5, and Japan)
16. Social Anxiety Disorder Access and Reimbursement Overview
17. KOL Views on the Social Anxiety Disorder Market
18. Social Anxiety Disorder Market Drivers
19. Social Anxiety Disorder Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Solutions
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States